X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (426) 426
humans (405) 405
sitagliptin phosphate (385) 385
male (333) 333
sitagliptin (319) 319
diabetes mellitus, type 2 - drug therapy (273) 273
animals (256) 256
pyrazines - pharmacology (229) 229
triazoles - pharmacology (227) 227
dipeptidyl-peptidase iv inhibitors - pharmacology (221) 221
pharmacology & pharmacy (220) 220
female (185) 185
type 2 diabetes (181) 181
hypoglycemic agents - therapeutic use (178) 178
hypoglycemic agents - pharmacology (169) 169
pyrazines - therapeutic use (167) 167
triazoles - therapeutic use (166) 166
middle aged (155) 155
diabetes (144) 144
dipeptidyl-peptidase iv inhibitors - therapeutic use (138) 138
glucagon-like peptide-1 (135) 135
rats (130) 130
endocrinology & metabolism (124) 124
sitagliptin phosphate - pharmacology (123) 123
hypoglycemic agents (120) 120
mice (108) 108
dipeptidyl peptidase-4 inhibitor (104) 104
aged (99) 99
glucose (97) 97
adult (96) 96
double-blind (95) 95
metformin (95) 95
blood glucose - metabolism (94) 94
triazoles - administration & dosage (94) 94
dipeptidyl peptidase 4 - metabolism (93) 93
pyrazines - administration & dosage (93) 93
glycemic control (92) 92
blood glucose - drug effects (91) 91
treatment outcome (91) 91
diabetes mellitus, type 2 - blood (84) 84
drug therapy, combination (83) 83
adamantane - analogs & derivatives (78) 78
insulin (78) 78
sitagliptin phosphate - therapeutic use (78) 78
hypoglycemic agents - administration & dosage (74) 74
diabetes mellitus (69) 69
research (68) 68
dosage and administration (66) 66
analysis (65) 65
pyrazines - adverse effects (63) 63
drug therapy (62) 62
efficacy (62) 62
hypoglycemic agents - adverse effects (62) 62
internal medicine (61) 61
triazoles - adverse effects (61) 61
dipeptidyl-peptidase iv inhibitors - administration & dosage (60) 60
glycated hemoglobin a - metabolism (58) 58
type-2 diabetes-mellitus (56) 56
care and treatment (54) 54
medicine, research & experimental (54) 54
safety (54) 54
glucagon-like peptide 1 - metabolism (52) 52
glucagon-like peptide 1 - blood (51) 51
diabetes therapy (50) 50
dose-response relationship, drug (49) 49
pharmacokinetics (49) 49
glp-1 (48) 48
glucagon (48) 48
oxidative stress (48) 48
diabetes mellitus, type 2 - metabolism (46) 46
double-blind method (46) 46
iv inhibitor (46) 46
metformin - therapeutic use (46) 46
rodents (46) 46
dipeptidyl-peptidase iv inhibitors - adverse effects (45) 45
adamantane - therapeutic use (44) 44
dipeptidyl-peptidase iv inhibitors (44) 44
mice, inbred c57bl (44) 44
pharmacology (44) 44
pyrazines - pharmacokinetics (44) 44
triazoles - pharmacokinetics (44) 44
dextrose (43) 43
metformin - pharmacology (43) 43
cross-over studies (42) 42
peptides (42) 42
rats, wistar (42) 42
disease models, animal (41) 41
inflammation (41) 41
medicine & public health (41) 41
vildagliptin (41) 41
administration, oral (40) 40
diabetes mellitus, type 2 - physiopathology (40) 40
incretins (40) 40
insulin - blood (40) 40
physiological aspects (40) 40
adamantane - pharmacology (39) 39
insulin - metabolism (39) 39
insulin resistance (39) 39
peptidase (39) 39
beta-cell function (38) 38
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (601) 601
French (5) 5
German (5) 5
Chinese (4) 4
Hungarian (4) 4
Japanese (2) 2
Dutch (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science Translational Medicine, ISSN 1946-6234, 04/2016, Volume 8, Issue 334, pp. 334ra51 - 334ra51
Journal Article
Diabetes Care, ISSN 0149-5992, 03/2016, Volume 39, Issue 3, pp. 455 - 464
Journal Article
Diabetes Care, ISSN 0149-5992, 2016, Volume 39, Issue 12, pp. 2304 - 2310
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 07/2017, Volume 174, Issue 14, pp. 2273 - 2286
Background and Purpose Results regarding protective effects of dipeptidyl peptidase 4 (DPP4) inhibitors in renal ischaemia–reperfusion injury (IRI) are... 
ACUTE KIDNEY INJURY | ISCHEMIA/REPERFUSION INJURY | ANIMAL RESEARCH | OSTEOPONTIN | SITAGLIPTIN | ALPHA CELLS | RATS | PHARMACOLOGY & PHARMACY | FACTOR-I | UP-REGULATION | ARRIVE GUIDELINES | Dipeptidyl Peptidase 4 - metabolism | Linagliptin - administration & dosage | Sitagliptin Phosphate - pharmacology | Kidney - pathology | Nitriles - pharmacology | Rats, Wistar | Reperfusion Injury - drug therapy | Pyrrolidines - administration & dosage | Male | Sitagliptin Phosphate - chemistry | Structure-Activity Relationship | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Pyrrolidines - pharmacology | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Kidney - metabolism | Molecular Structure | Adamantane - administration & dosage | Reperfusion Injury - metabolism | Adamantane - analogs & derivatives | Linagliptin - pharmacology | Sitagliptin Phosphate - administration & dosage | Adamantane - pharmacology | Kidney - drug effects | Reperfusion Injury - pathology | Rats | Dipeptidyl-Peptidase IV Inhibitors - chemistry | Pyrrolidines - chemistry | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Linagliptin - chemistry | Animals | Nitriles - chemistry | Adamantane - chemistry | Comparative analysis | Reperfusion injury | Cystatin | Damage assessment | Peptidase | Renal artery | Glucagon | Osteopontin | Biomedical materials | Inhibitors | Reperfusion | Ischemia | Rodents | Cystatin C | Biocompatibility | Plasma levels | Mathematical models | Inhibition | Research Papers | Research Paper
Journal Article
Journal Article
American Journal of Physiology - Heart and Circulatory Physiology, ISSN 0363-6135, 2015, Volume 309, Issue 9, pp. H1528 - H1542
Cardiac sympathetic nerves release neuropeptide Y (NPY)(1-36), and peptide YY (PYY)(1-36) is a circulating peptide; therefore, these PP-fold peptides could... 
Cell proliferation | Neuropeptide Y | Dipeptidyl peptidase 4 | Receptor for activated C kinase 1 | Cardiac fibroblasts | Peptide YY | Spontaneously hypertensive rats | FIBROSIS | NERVOUS-SYSTEM | CARDIAC & CARDIOVASCULAR SYSTEMS | PHYSIOLOGY | cell proliferation | RAT | cardiac fibroblasts | peptide YY1-36 | HEART-FAILURE | SITAGLIPTIN | ANGIOTENSIN-II | VASCULAR SMOOTH-MUSCLE | NEUROPEPTIDE-Y | receptor for activated C kinase 1 | spontaneously hypertensive rats | RENAL VASOCONSTRICTION | PERIPHERAL VASCULAR DISEASE | dipeptidyl peptidase 4 | neuropeptide Y1-36 | Peptide YY - pharmacology | Sitagliptin Phosphate - pharmacology | Maleimides - pharmacology | Rats, Inbred WKY | Peptide Fragments - pharmacology | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Type C Phospholipases - antagonists & inhibitors | Collagen - drug effects | Estrenes - pharmacology | Pyrrolidinones - pharmacology | Receptors for Activated C Kinase | Indoles - pharmacology | Collagen - biosynthesis | Hypertension - genetics | Fibroblasts - metabolism | Pertussis Toxin - pharmacology | Rats, Inbred SHR | Angiotensin II - pharmacology | Signal Transduction | Rats | Neuropeptide Y - pharmacology | Protein Kinase C - antagonists & inhibitors | Myocardium - cytology | Animals | Fibroblasts - drug effects | Cell Proliferation - drug effects | GTP-Binding Proteins - metabolism | Cardiovascular Neurohormonal Regulation | peptide YY1–36 | neuropeptide Y1–36
Journal Article
Journal of Gastroenterology and Hepatology, ISSN 0815-9319, 03/2015, Volume 30, Issue 1, pp. 60 - 65
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 5/2018, Volume 74, Issue 5, pp. 561 - 569
Journal Article
Nature, ISSN 0028-0836, 03/2018, Volume 555, Issue 7698, pp. 673 - 677
Obesity-induced metabolic disease involves functional integration among several organs via circulating factors, but little is known about crosstalk between... 
TISSUE INFLAMMATION | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | GLYCEMIC CONTROL | DOSE-RESPONSE | LINKING OBESITY | MACROPHAGES | MULTIDISCIPLINARY SCIENCES | ENDOTHELIAL-CELLS | BODY-MASS INDEX | TYPE-2 DIABETES-MELLITUS | EXPRESSION | Dipeptidyl Peptidase 4 - metabolism | Sitagliptin Phosphate - pharmacology | Humans | Receptor, PAR-2 - metabolism | Male | Hepatocytes - metabolism | Receptor, PAR-2 - deficiency | Obesity - genetics | Inflammation - metabolism | Hepatocytes - drug effects | Receptor, PAR-2 - genetics | Sitagliptin Phosphate - administration & dosage | Administration, Oral | Caveolin 1 - genetics | Caveolin 1 - deficiency | Dipeptidyl Peptidase 4 - genetics | Intra-Abdominal Fat - metabolism | Factor Xa - metabolism | Obesity - metabolism | Caveolin 1 - metabolism | Macrophages - metabolism | Animals | Dipeptidyl Peptidase 4 - deficiency | Insulin Resistance - genetics | Inflammation - genetics | Mice, Obese | Mice | Obesity - enzymology | Intra-Abdominal Fat - pathology | Inflammation - enzymology | Hepatocytes - enzymology | Physiological aspects | Obesity | Insulin resistance | Observations | Caveolin-1 | Peptidase | Adipose tissue | Caveolin | Liver | Crosstalk | Oral administration | Organs | Inflammation | Kinases | Macrophages | Insulin | Proteins | Disease resistance | Functional integration | Hepatocytes | Rodents
Journal Article
Journal Article
Journal Article
Journal Article